Rodney Prell PhD

Dr. Prell is currently a principal scientist/toxicologist in the Safety Assessment Department at Genentech. He is currently the Safety Assessment Therapeutic Area Lead for the cancer immunology portfolio. He received his PhD in Toxicology, specializing in Immunotoxicology, from Oregon State University in 1997. He completed his post-doctoral training at Earle A. Chiles Research Institute in Portland, Oregon (1997-2001) where he studied antibody-based cancer immunotherapeutic approaches. He previously worked at Onyx Pharmaceutical, Cell Genesys and Cerus where he was responsible for leading nonclinical safety and pharmacology efforts using various cancer immunotherapy vaccine approaches. Dr. Prell joined Genentech in 2007 and has served as a project toxicologist on over 15 biologic therapeutic candidates for infectious disease, oncology, immunology and cancer immunotherapy indications.